New Edge Advisors, LLC Moleculin Biotech, Inc. Call Options Transaction History
New Edge Advisors, LLC
- $13.5 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding MBRX
# of Institutions
2Shares Held
3.35KCall Options Held
0Put Options Held
0About Moleculin Biotech, Inc.
- Ticker MBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,606,700
- Market Cap $83.2M
- Description
- Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs....